<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>1471-2148-7-2.fm</title>
<meta name="Author" content="petere"/>
<meta name="Creator" content="FrameMaker 7.0"/>
<meta name="Producer" content="Acrobat Distiller 7.0 (Windows)"/>
<meta name="CreationDate" content=""/>
</head>
<body>
<pre>
BMC Evolutionary Biology

BioMed Central

Open Access

Research article

Inventing an arsenal: adaptive evolution and neofunctionalization of
snake venom phospholipase A2 genes
Vincent J Lynch*

Address: Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, 06511, USA
Email: Vincent J Lynch* - vincent.j.lynch@yale.edu
* Corresponding author

Published: 18 January 2007
BMC Evolutionary Biology 2007, 7:2

doi:10.1186/1471-2148-7-2

Received: 02 October 2006
Accepted: 18 January 2007

This article is available from: http://www.biomedcentral.com/1471-2148/7/2
Â© 2007 Lynch; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background: Gene duplication followed by functional divergence has long been hypothesized to
be the main source of molecular novelty. Convincing examples of neofunctionalization, however,
remain rare. Snake venom phospholipase A2 genes are members of large multigene families with
many diverse functions, thus they are excellent models to study the emergence of novel functions
after gene duplications.
Results: Here, I show that positive Darwinian selection and neofunctionalization is common in
snake venom phospholipase A2 genes. The pattern of gene duplication and positive selection
indicates that adaptive molecular evolution occurs immediately after duplication events as novel
functions emerge and continues as gene families diversify and are refined. Surprisingly, adaptive
evolution of group-I phospholipases in elapids is also associated with speciation events, suggesting
adaptation of the phospholipase arsenal to novel prey species after niche shifts. Mapping the
location of sites under positive selection onto the crystal structure of phospholipase A2 identified
regions evolving under diversifying selection are located on the molecular surface and are likely
protein-protein interactions sites essential for toxin functions.
Conclusion: These data show that increases in genomic complexity (through gene duplications)
can lead to phenotypic complexity (venom composition) and that positive Darwinian selection is a
common evolutionary force in snake venoms. Finally, regions identified under selection on the
surface of phospholipase A2 enzymes are potential candidate sites for structure based antivenin
design.

Background
Phospholipase A2s (PLA2; EC 3.1.1.4) are esterolytic
enzymes that hydrolyze glycerophospholipids at the sn-2
fatty acyl bond, releasing lysophospholipids and fatty
acids. PLA2s play key roles in various biological processes
in mammals including signal transduction, lipid digestion, host defense and production of eicosanoids and
other lysophospholipid derivates with potent biological
activities [1]. PLA2 enzymes are also the major compo-

nents of snake venoms where they function to immobilize
and rapidly kill prey [1]. PLA2s from elapid venoms
(group-I) are structurally similar to pancreatic secretions
while PLA2s from viper venoms (group-II) are structurally
similar to inflammatory secretions [2]. A third group of
PLA2s (group-III) have been identified from the venom of
bees, jellyfish, scorpions and lizards [2] indicating that
PLA2s have been recruited into a toxic function multiple
times in diverse lineages.
Page 1 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

Snake venom PLA2s are members of large multigene families with diverse pharmacological activities including
neurotoxic, myotoxic, cardiotoxic, anticoagulant and
hemolytic effects [2]. These diverse activities evolved from
an ancestral nontoxic PLA2 by a process of repeated gene
duplication followed by functional divergence. PLA2 toxicity is independent of enzymatic activity [3,4] and is
mediated through "pharmacological sites" on the protein
surface that directly interact with ligands on the cell membrane [5]. Thus, the surface of PLA2s forms a scaffold for
adaptive modification that has been used to generate a
diverse array of pharmacological effects through a process
of neofunctionalization (the generation of new protein
functions that were not the primary function of the ancestral protein).
Previous studies of PLA2 genes identified accelerated evolution of group-I genes from Naja naja [6] and group-II
genes from Trimeresurus [7] and Vipera [8] consistent with
positive Darwinian selection, however these studies
focused on one or two species, included relatively few
genes and used methods that lack power to detect episodic
adaptive evolution. A larger study of group-I and -II genes
found that amino acid substitutions were correlated with
surface accessibility [9], suggesting that modifications of
surface residues and positive selection play important
roles in generating toxin diversity. To further explore this
possibility I compiled an extensive dataset of full length
snake venom PLA2 genes from public databases, inferred
the gene trees for these toxins and tested for episodes of
positive Darwinian selection coincident with the origin of
novel pharmacological effects and recurrent diversifying
selection on specific sites. In addition, I used a larger
amino acids dataset to test if conclusions drawn from the
smaller nucleotide dataset were robust to phylogenetic
inference.
The results indicate that adaptive evolution is common in
snake venom PLA2 genes and is associated with the evolution of new toxin functions and speciation events, demonstrating that molecular adaptation has played a
pervasive role in the evolution of snakes and their venom
arsenal. This analysis has identified the mutational pathway leading from non-toxic to highly toxic PLA2 enzymes,
reconstructing the processes of mutation and adaptation.
Finally, increases in genomic complexity gained through
gene duplications has promoted the evolution an increasingly complex phenotype (venom composition), providing a link between molecular, phenotypic and organismal
evolution.

Results and discussion
Gene duplication and speciation history
To study the molecular evolution of snake venom PLA2
genes, I compiled a dataset of 83 group-I and 90 group-II

http://www.biomedcentral.com/1471-2148/7/2

genes from public databases and inferred the evolutionary
history of these genes using Bayesian phylogenetics [10].
The molecular phylogeny inferred for group-I PLA2
enzymes (Figs. 1 and 3) indicates that genes group with
higher-order snake phylogeny and are divided into two
sister clades containing marine and Australian species (the
"Hydrophiids") and African, American and Asian species
(the "Elapids"). This division is similar to the results of
earlier phylogenetic studies of group-I PLA2 genes [11]
and likely reflects a deep divergence between these
groups. Within these two major clades, subclades contain
genes from closely related taxa that have similar pharmacological effects, suggesting functional diversification
occurred after speciation. In contrast, group-II genes cluster by pharmacological effect with little species distinction
(Figs. 2 and 4), indicating that functional divergence arose
before the divergence of these species.
Even though branch support for the group-I and group-II
nucleotide trees was high in this analysis, nucleotide data
are only about a third of the gene sequences that are available, the majority are amino acid data (and thus not suitable for codon-based selection analysis discussed later).
To test if the topology of nucleotide-based gene trees was
sensitive to taxon sampling I inferring group-I and groupII phylogenies using larger amino acids datasets (245
group-I and 271 group-II genes, respectively). Although
the trees inferred from amino acid data (Figs. 3 and 4) had
lower support for recent lineages than the nucleotide data,
perhaps because protein sequences have not accumulated
enough phylogenetically informative substitutions to
accurately reconstruct recent branching orders, the deeper
nodes were well supported and the overall topology was
congruent between amino acid and nucleotide data indicating that inferences based on the nucleotide datasets are
reliable.
Origin and elaboration of toxic genes
Snake venom PLA2s have diverse pharmacological activities including neurotoxic, myotoxic, cardiotoxic, anticoagulant and hemolytic effects [2], which must have
originated after they diverged from nontoxic ancestors.
Although uncertainty in the tree topology and the richness
of toxin functions makes assessment of specific ancestral
and derived functions difficult for all lineages, it is clear
from these phylogenies that many novel functions have
originated in PLA2 genes after gene duplications. For
example, three nontoxic group-I PLA2 genes isolated from
Laticuadata semifasciata pancreas [12] branch near the base
of the Elapinae group in the nucleotide tree, but are the
most basal snake group-I genes in the amino acids tree
(Figs. 1 and 3). These pancreatic genes have been suggested to be intermediates between nontoxic and toxic
enzymes [12], suggesting that duplication of an ancestral
nontoxic gene originally expressed in the pancreas was

Page 2 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

L.laticaudata.17129631
L.laticaudata.17129629
L.laticaudata.64047
L.laticaudata.17129627
L.laticaudata.17129625
L.colubrina.17129637
L.colubrina.17129639
L.colubrina.17129633
L.semifasciata.9453877
L.semifasciata.9453907
L.semifasciata.9453879
L.semifasciata.9453881
L.semifasciata.9453909
L.semifasciata.17129623
L.semifasciata.9049438
L.semifasciata.17129621
L.semifasciata.9453913
A.superbus.5924334
A.laevis.62401
N.scutatus.64105
A.superbus.27802488
A.superbus.5924322
A.superbus.5924330
A.superbus.5924320
A.superbus.5924324
A.superbus.5924326
A.superbus.5924328
A.superbus.5924332
A.superbus.5924336
N.scutatus.64109
A.superbus.5924342
A.superbus.5924346
A.superbus.5924348
A.superbus.5924344
A.superbus.5924340
A.superbus.5924338
L.hardwickii.18000322

A

L.hardwickii.18026637
A.superbus.5923907
A.superbus.5923909
L.semifasciata.21734659
L.semifasciata.21734661
L.semifasciata.21734657
O.hannah.10442707
O.hannah.10863759
O.hannah.10863761
N.naja.804797
N.sputatrix.8953898
N.naja.804793
N.naja.804795
N.sputatrix.8953900
N.naja.395191
N.naja.456270
N.kaouthia.4115522
N.kaouthia.4115520
M.corallinus.24496494
B.caeruleus.10121879
B.multicinctus.62501
B.fasciatus.14423357
B.fasciatus.14423359
B.caeruleus.19526594
B.multicinctus.24412702
B.multicinctus.62505
B.multicinctus.1000449
B.multicinctus.19069523
B.multicinctus.24412704
B.multicinctus.24412706
B.multicinctus.6523108
B.multicinctus.6523110
B.candidus.24459191
B.multicinctus.62473
B.multicinctus.24412700
B.multicinctus.24412708
B.multicinctus.10129662
B.candidus.24459193
B.multicinctus.6523112
B.candidus.24459189
B.caeruleus.19526596
B.candidus.29422776
P.textilis.5230717
P.textilis.19067870
P.textilis.5230715
P.textilis.19067868

100| 1.76
100| (14/0)
100| 2.11

B

100| 2.04

100

100|(16/0)

1.19
1.03

85| 2.65
53

94
(22/0)

95
60| 1.77

94

75
1.39
68| (7/0)

97| 3.20

93
90

95| 1.02
99| 1.58

99| (21/0)

96| 2.29

1.83

53

100| 5.50
100| 1.24

100| 1.29

100| 3.91

4.67
89

92

94

98

3.62

99| 1.26
91| (11/0)

2.16
100| 3.34
1.29
1.10

100
79| 2.89
93
100|(14/0)

2.19

84

84| 1.28
68

95

100
100| 2.33

100

72

100| 1.63

85

(4/0)
1.81
100| 3.06

100| 4.06

100

59

1.67

62| (6/0)
62

82

76
91| 9.06
64| (6/0)

85| 5.12

55| 1.35

97

65| 1.29
(12/0)

72

94| 1.07

1.23
95| 3.49

100
100| 1.30

2.9
(5/0)

L.laticaudata.17129631
L.laticaudata.17129629
L.laticaudata.64047
L.laticaudata.17129627
L.laticaudata.17129625
L.colubrina.17129637
L.colubrina.17129639
L.colubrina.17129633
L.semifasciata.9453877
L.semifasciata.9453907
L.semifasciata.9453879
L.semifasciata.9453881
L.semifasciata.9453909
L.semifasciata.17129623
L.semifasciata.9049438
L.semifasciata.17129621
L.semifasciata.9453913
A.superbus.5924334
A.laevis.62401
N.scutatus.64105
A.superbus.27802488
A.superbus.5924322
A.superbus.5924330
A.superbus.5924320
A.superbus.5924324
A.superbus.5924326
A.superbus.5924328
A.superbus.5924332
A.superbus.5924336
N.scutatus.64109
A.superbus.5924342
A.superbus.5924346
A.superbus.5924348
A.superbus.5924344
A.superbus.5924340
A.superbus.5924338
L.hardwickii.18000322
L.hardwickii.18026637
A.superbus.5923907
A.superbus.5923909
L.semifasciata.21734659
L.semifasciata.21734661
L.semifasciata.21734657
O.hannah.10442707
O.hannah.10863759
O.hannah.10863761
N.naja.804797
N.sputatrix.8953898
N.naja.804793
N.naja.804795
N.sputatrix.8953900
N.naja.395191
N.naja.456270
N.kaouthia.4115522
N.kaouthia.4115520
M.corallinus.24496494
B.caeruleus.10121879
B.multicinctus.62501
B.fasciatus.14423357
B.fasciatus.14423359
B.caeruleus.19526594
B.multicinctus.24412702
B.multicinctus.62505
B.multicinctus.1000449
B.multicinctus.19069523
B.multicinctus.24412704
B.multicinctus.24412706
B.multicinctus.6523108
B.multicinctus.6523110
B.candidus.24459191
B.multicinctus.62473
B.multicinctus.24412700
B.multicinctus.24412708
B.multicinctus.10129662
B.candidus.24459193
B.multicinctus.6523112
B.candidus.24459189
B.caeruleus.19526596
B.candidus.29422776
P.textilis.5230717
P.textilis.19067870
P.textilis.5230715
P.textilis.19067868

Figure 1 phylogeny of group-I phospholipase A2 genes
Molecular
Molecular phylogeny of group-I phospholipase A2 genes. (A) Bayesian phylogeny, branch lengths are given as number of substitutions per codon. (B) Evolution of group-I genes. Numbers above the branches are Bayesian posterior probability values (BP)
followed by the dN/dS ratio (Ï) or the number of nonsynonymous substitutions (N) if no synonymous substitutions (S)
occurred along that branch (BP | Ï or N/S). Branches in red were inferred to be under positive selection. Genes are labeled
according the species they were identified from followed by the GenBank GI number for that gene. Pharmacological effects and
higher order classifications are given to the right of clades. Pan, nontoxic pancreatic isoforms. AtC, anticoagulent. Ctx, cardiotoxic. PrC, procoagulent.

Page 3 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

T.mucrosquamatus.7636221
Ca.rhodostoma.6073845
Ca.rhodostoma.6073844
T.jerdonii.20977210
E.ocellatus.25992664
V.ammodytes.871759
V.ammodytes.64448
V.ammodytes.296137
V.ammodytes.64441
V.ammodytes.2231121
V.ammodytes.64444
T.flavoviridis.28268776
T.flavoviridis.28268778
T.mucrosquamatus.895913
P.mucrosquamatus.15420984
D.acutus.1177378
C.durissusCtB2.62696
C.durissusCtB.62692
C.scutulatusMtB.451317
B.jararacussu.475923
B.jararacussu.28194388
T.mucrosquamatus.1177690
D.acutus.1177376
D.acutus.1177379
Ca.rhodostoma.6073834

A

Ca.rhodostoma.6073832
Ca.rhodostoma.6073846
Ca.rhodostoma.6073847
T.flavoviridis.222954
T.flavoviridis.222952
B.asper.6492259
B.neuwiedi.7673018
B.jararacussu.28194117
B.moojeni.7673016
B.schlegelii.17432517
C.godmani.17432519
C.atro.17224434
A.contortri.809484
T.gramineus.992956
T.gramineus.994789
T.gramineus.994787
D.acutus.17224438
A.acutus.2760480
T.okinavensis.1469806
T.flavoviridis.21698859
T.flavoviridis.15799260
T.flavoviridis.222956
G.halys.2460024
G.halys.2460026
T.mucrosquamatus.517489
T.flavoviridis.222958
T.flavoviridis.222960
T.flavoviridis.15799262
T.flavoviridis.15799264
T.okinavensis.1469804
T.gramineus.992955
G.halys.2460034
C.durissusCtA.62685
C.scutulatusMtA.451315
B.pictus.9652396
C.viridis.28893825
C.viridis.28893821
C.viridis.29692355
C.atro.17224436
C.viridis.29692349
C.viridis.29692351
C.viridis.29692353
C.viridis.28893823
Ca.rhodostoma.6073842
Ca.rhodostoma.6073838
Ca.rhodostoma.6073840
Ca.rhodostoma.6073836
D.acutus.1177377
B.jararacussu.25140376
B.insularis.20069136
A.piscivorus.263959
G.halys.2460030
G.halys.2460028
E.coloratus.13936544
E.carinatus.25992660
E.pyramidum.25992662
E.coloratus.13936542
V.palaestinae.1575330
V.aspis.22797864
V.russelli.64454
V.russelli.30142139
V.ammodytes.5702035
V.ammodytes.6967297
V.russelli.64452
V.aspis.22797866

100

100 |1.54

B
B

100

51| (3/0)

100

62| 3.97

100 | 2.17
94

100| 1.59

78| (11/0)

100

100

100

76
98| 2.32
100 |1.21

97

99| (5/0)

100
89
74| (5/0)
100
62| (10/0)

100

59| (6/0)

100| 1.4
100| 1.62

100
100 | 1.68

100

100 | 1.26
83

100
94| 2.35

91

100| 3.85

92
2.44

100 | 1.65
71

100| 1.99

100
100 | 1.5
100

88

100

100
100 | (8/0)

87
51
100

100
100 | (10/0)
88

88| 2.71

78

93

94
93| 1.43

100| 1.03
100

71| (9/0)
92| 2.38

67| 1.22

100

100 | 1.02

100| 1.29
100
100

100
65
99| (23/0)
98
97| 2.48

100 | 3.67

2.44

T.mucrosquamatus.7636221
Ca.rhodostoma.6073845
Ca.rhodostoma.6073844
T.jerdonii.20977210
E.ocellatus.25992664
V.ammodytes.871759
V.ammodytes.64448
V.ammodytes.296137
V.ammodytes.64441
V.ammodytes.2231121
V.ammodytes.64444
T.flavoviridis.28268776
T.flavoviridis.28268778
T.mucrosquamatus.895913
P.mucrosquamatus.15420984
D.acutus.1177378
C.durissusCtB2.62696
C.durissusCtB.62692
C.scutulatusMtB.451317
B.jararacussu.475923
B.jararacussu.28194388
T.mucrosquamatus.1177690
D.acutus.1177376
D.acutus.1177379
Ca.rhodostoma.6073834
Ca.rhodostoma.6073832
Ca.rhodostoma.6073846
Ca.rhodostoma.6073847
T.flavoviridis.222954
T.flavoviridis.222952
B.asper.6492259
B.neuwiedi.7673018
B.jararacussu.28194117
B.moojeni.7673016
B.schlegelii.17432517
C.godmani.17432519
C.atro.17224434
A.contortri.809484
T.gramineus.992956
T.gramineus.994789
T.gramineus.994787
D.acutus.17224438
A.acutus.2760480
T.okinavensis.1469806
T.flavoviridis.21698859
T.flavoviridis.15799260
T.flavoviridis.222956
G.halys.2460024
G.halys.2460026
T.mucrosquamatus.517489
T.flavoviridis.222958
T.flavoviridis.222960
T.flavoviridis.15799262
T.flavoviridis.15799264
T.okinavensis.1469804
T.gramineus.992955
G.halys.2460034
C.durissusCtA.62685
C.scutulatusMtA.451315
B.pictus.9652396
C.viridis.28893825
C.viridis.28893821
C.viridis.29692355
C.atro.17224436
C.viridis.29692349
C.viridis.29692351
C.viridis.29692353
C.viridis.28893823
Ca.rhodostoma.6073842
Ca.rhodostoma.6073838
Ca.rhodostoma.6073840
Ca.rhodostoma.6073836
D.acutus.1177377
B.jararacussu.25140376
B.insularis.20069136
A.piscivorus.263959
G.halys.2460030
G.halys.2460028
E.coloratus.13936544
E.carinatus.25992660
E.pyramidum.25992662
E.coloratus.13936542
V.palaestinae.1575330
V.aspis.22797864
V.russelli.64454
V.russelli.30142139
V.ammodytes.5702035
V.ammodytes.6967297
V.russelli.64452
V.aspis.22797866

Molecular phylogeny of group-II (B) phospholipase A2 genes
Figure 2
Molecular phylogeny of group-II (B) phospholipase A2 genes. (A) Bayesian phylogeny, branch lengths are given as number of
substitutions per codon. (B) Evolution of group-II genes. Numbers above the branches are Bayesian posterior probability values (BP) followed by the dN/dS ratio (Ï) or the number of nonsynonymous substitutions (N) if no synonymous substitutions (S)
occurred along that branch (BP | Ï or N/S). Branches in red were inferred to be under positive selection. Genes are labeled
according the species they were identified from followed by the GenBank GI number for that gene. Pharmacological effects and
higher order classifications are given to the right of clades. AtC, anticoagulent. Chp/Chaperone, neurotoxin chaperone. Ntx,
neurotoxic.

Page 4 of 14
(page number not for citation purposes)

http://www.biomedcentral.com/1471-2148/7/2

100

100

100

N.sagittifera 66360668
99
N.sagittifera 58197903
100
N.naja 31615941
61
66360669
N.sagittifera 58197905
100 92
ra
75
N.sagittife
5584
fera 3161 31
N.Sagittiifera 460157 78
58
N.Sagitt ra 385654 22
100
ittife 383245
75
N.sag
8
99 100
ittifera 3335732 6
N.sag
ra
1558
86
gittife 316
N.sa gittifera 379265 91
3
ra
042 2
N.Sa
76
gittife a 71 516
100
N.Sa gittifer 4842 7492
1
5
N.sa gittiferaa 380 155832
a tifer
16 57
N.s
ra 3 601 4 8 9
agit
N.s gittifeera 4 7700 411
9 4
a
3
if
N.S agitt ifera a 122951 04
N.S agitt xian ja 1 641 88
83
1 5
N.s N . o a a
N.n .naj 443 835 9
N tra 55 4 6 2
8 9
78
a
N. naja 4 6 3 951 4 6 8
2
N. a 2 3 8
a 3 44 9
t h i aj 46 29 40 2
o u .n 2 1 29 3 2
ka N thia uca a 1 294 42 33
N.
1 29 4
ou le uc
9
ka no le ca 1 2
N. ela no leu tu 1
m la o ta ica
N. .me lan scu b
N me ps sam
N. ela os
d
pi N.m

As

N
.m
os
sa
m
o N m
N . s s a .pa b i c
N . n m ll a
s p i g r b ida 1
ut ic ic 1 2
N
N. .sp atr olli a 2 94
s
u ix s 1 9 1
N . p u t t a t r 2 5 1 2 2 9 4 515 0
sp atr ix 4 9 4
60
ut ix
8 53 44 3
N. N.k atrix 25 953 1624
66 10 1
ka a
45 9
0 00 92
B.f outhouth 8953 316 01
O . h as
ia ia
8 3
O.H ann ciatu 214671 99
50
73
O.h ann ah 1 s 12 44472
0
M.I annaah 3 08639494
89
kah h 1 480 76
63 82 59
2
M.I
e
kah ka 5 08639960
M.Ik ek
7
5
100
ahe a 55 6695 60
44
k
6
P.te
xtilis P.texti a 616769537
extilo lis 7
979
55 100
toxin 1066 7
100
7
D
A.su P.textilis chain 746
100
pe
1
26
A.sup rbus 592 5536
erbus
3
O.scu
592 908 100 100
O.scute tellatus 1 3910
29446
llatus
10098
77
O.micro
lepidotu 66475086
O.scutellat s 71066734
us 710667
100
O.scutellatus
22
99
71066724
96
O.scutellatus 913
013
100
O.scutellatus 71066720
80
P.textilis 19067869
19067871
P.textilis
Lapemishardwickii 18026638
4327 10099
A.superbus 592
50
100
5924329
96
A.superbus 5924331
us
93
97
A.superb
5924325
100
superbus 27802489
A.
100
bus
323
A.supererbus 5924 183
100
A.sup cutatus 67 110
64
N.s
s 64 758
tatu
6
N.scu s 7106 4333
92
2
utatu
100
N.sc erbus 5 2416006
88
1
p
s
A.su cutatu tus 64 337
N.s cuta 5924 335
00
N.s rbus 5924 02
86 1
6 2 4 86
upe us
0
A.s uperb evis 4729 88
0 10
A.s rusla ii 49 4729964
10
ysu doux ii 499472 29920
Aip .ey oux i 4 47 98
A yd uxi 49 72 76
A.e ydo uxii 494 729984 6
A . e y d o u x i i 4 9 44 7 2 2 9 6 2
A.e eydo uxii i 49 947 29890
A . e y d o o u x i i i 4 9 4 77 2 9 9 7 0 8
A. eyd oux ii 4 94 472 297 9 6
A. .eyd oux xii 4 49 47 6 7
A eyd ou xii 49 0 6
A. eyd dou uxii 7 1
A. .ey do u s
A .ey i a c
A hyr
p
or
.p
P

N.

N.naja 31615940
Hemachatushaemachatus 129403
M.nigrocinctus 3914267
M.nigrocinctu
M.corallinus s 3914266
24496495
B.candid
100
B.flavic us 29422777
B.fla eps 31745051
B.muviceps 317
100
lt
99
B.m icinctus 6 45049
562
99 9 10
B.m ulticin
5 0 B.m ulticincctus 656 011
6 83
2013
tus 1
ultic
68 2
B.m
in
ultic ctus 6 359511
B.m
2506
B.c ultic inctus
68
B.m andidinctus 10129
B.m ultic us 3 6523 663
B.m ultic inctu 4368 113
B.m ultic inctu s 656 939
200
64
B ul inc s 6
9
B . c a tici tus 5 2 3
B . c a n d i d nctu 624 1 1 1
B . . c a e e r u l u s 4 s 35 74
B. mul r u l e e u s 0 3 6 0799
u
3
B m ti
1
B .m ulti cinc s 1 9 5 2 6 8 9
B .m ul cin tu 9 5 6 5
B. .m ulticticin ctus s 24 2659 97
m ult in ctu 1 41
5
B
2
B .m u ic c s 4
B . .m ul lticin inct tus 65 3175 709
c a ult tic ct us 65 23
5
n d ici inc us 6 62 109
52 02
i d nc tus 24 2
u s tu 1 4 9 2
s
1 5
3 8 23 90 27 3
0 1 39 695 05
6 9 67 24
6 5 80

BMC Evolutionary Biology 2007, 7:2

81

92

81
71

10
0

52

81

63

100

100

84

P.

100

2
63 0
33 2 9 6 3
55 7 1 2 9 2 8
26 a 1 1 7 1 2 9 6 6 2 6
71 29
ilis a t
xt u d a t a 1 7 1 8 1 6 6 9
.te a d a 1 0 4 5 3
16
ic u at a
Pn . l a t t i c a a u d d a t a 6 4 2 5 4 4 5 3 1 6 8
L .la tic a u at t a 2 5 5 3 6 7
L .la t i c ud c i a t a 5 4 3 1 0
0
2
5
7
L l a ca s i a
10
L . .lati m i f a a s c i a t a 2 5 4 5 3 1
L .se mif asc iata 254 39
83 100
L .se if c ta 294 50
1 4
L
em ifas cia
4
93
L.ssem ifas ciataa 129 2962 5
L. sem ifas ciat 171 5316
L. sem ifas iata 254 39
L.
494
em asc ta
L.ssemififascia ta 90 41
100
81 60 65 99
L. sem ascia 9243 3
L. semif us 5 2434
rb
59
45
L.
243
upe us
89
A.s uperb us 59 4349
A.s
perb us 592 347
00
A.su
921
5924
9
perb
100 98 7198
A.su perbuss 592433
A.su perbu
34
100
A.su tatus 1294 976
7
N.scu tus 109
99 97 N.scuta tus 71066754
100
N.scuta s 71066756
100
N.scutatu 129445
79
100
N.scutatus 129509
87
E.schistos
6640
Lapemishardwickii 1802
L.hardwickii 18000323
L.colubrina 17129640

Pe P
.a .a
po
us us
P . r p h P.a tr a tra
p o y r u l is lis
A . r p i a st 7 1
c u ra 1 2
P . A an h y s l 0 9
is
p o .a tar r i a
7 1 66 47
r n
c
P . p h y t a r c t i c u c u s 1 0 29 78 6
6 4 6
p
r t
P e o r p h i a c u i c u s s 3 1 2 9 6 7 9 74
.au y r s 3 18 4 4
94 10
7 1 3 5
s ia
0
P.a trali c u s 1 0 6 831 114 9
P.a ustr s 71 12 67915
10
Pe ust alis 06 9 4 6 8
0
91
Pe .aust ralis 129 67885
Pe
10
. a u .aust ralis 129 454
0
10
ra
s
3
97
0
P.a tralis lis 11294 97
5
Pe.
Pe. ustrali 71062947 2
94 99
por
phy austr s 12 67761
77
P.a riacus alis 1 9415
us
2
100
P.au tralis 710669458
100
89
Pe.a stralis 710667792
7
u
8
P.au stralis 7 106678 4
100
strali
1066 0
P.aus s 71066 782
778
trali
92 76
Pe.porp P.austra s 129477
1
100 000 100
hyriacus lis 1294
10
Pe.porph
710667 47
yriacus
90
100
L.colubrin71066800
a 12
L.colubrina 9428
100
L.colubrina 171 85961
62
29638
L.colubrina 17129636
10099
99
L.colubrina 17129634

92

10
0

98

64

100

10
0

82

70

61

100

100

96

84

84
100
100

83

91

0
19 9
59 96 2
4 4 0 1 6 1 9 703
2
9
s 3 8 4 5 412 7
4 4 5
du s
di du s 2 2 450 55 0
an ndi idu ctus317 450 188 1
c
B . . c a a n d icin p s 3 1 7 0 1 2 6 3 7 2
1 09
0
B . c ult i c e p s
B .m a v c e u s 1 3 7 8 7 4 8
B .fl avi r u l e u s 1 4 2 7 4 0 3
B .fl e u l e s 8 3 6 0 0
B .ca aer leu s 3 69 725
B .C eru eu
52 3
83
B .ca rul eus 4256 9299
B .cae erul us 925 4050
0
B .Ca rule us 4 837 923
10
e ule s 3 356
0
B .ca r
10
B ae leu 33
02
0
94 100 B.ccaeruuleustus 625 460
10 97
0
B. caer inc
. ultic tus 35 55
00 100
B m
1
c
4
B. ulticin s 129 462
100
B.masciatu s 129 3358
100
B.f asciatu 1442 3
s
.f
94
tu
B
945
98 00 B.fascia tus 124423360
cia
1
100
B.fas ciatus 1 9497
100
as
12
B.f
iatus
83
100
B.fasc iatus 2630 95
B.fasc dus 403636
B.candi ah 10442708
45
O.hann
iata 254531
100
L.semifasc ta 25453146
L.semifascia
100
Hum an
Sus
8899 T.carinatus 71066772
87
T.carinatus 71066770
80
T.carinatus 71066768
99
76
T.carinatus 710
66764
T.carinatus
N.scutatus 71066766
9993
N.scuta
tus 710620
T.car
6760
98
N.scuinatus 71
O.scu tatus 71 066774
75 79 100 00
1
O.sc tellatus 6066762
100100 54
utella
6475
O.sc
09
tu
100
O.s utellatu s 66475 0
s 71
092
O.s cutell
0
94
O.m cutell atus 9 66730
O.m icro atus 1301
100
O.m icro lepido 71066 4
83
726
O. icro lepid tus
10
O.smicro lepid otus 771066
0
742
10
O cu lep otu
O. .scut tellat idotu s 710 66736
10 9
us
66
s
99 0 9
P sc e l
P. .tex u t e l l l a t u s 7 1 0 7 1 0 6 7 3 8
tex tili a t u a l
66
O
p
s
72 6740
10
8
O . s c tili 4 s 1 h a
0 51
O . s u t e s 26 007 2 9 t a i p
O . s c c u t l l a 55 16 4 1 3 o x i n
2p
P . . m i u t ee l l a t t u s 34
re
P. te c r o l l a u s 7 1
P te xt l t u 6 0
P. . t e x x t i l i l i s t e p i d s 6 7 1 9 6 6 7
18
te t i l i s e x o t 6 4 4
xt i s 7 1 t i l u s 7 5
ilis 7 0 o t
7 0
26 1 0 6 6 6 7 o x i n 1 0 8 2
55 6 7 5 0 C 6 6 7
71
35 5 2
3
06 2
67

Figure 3 phylogeny of group-I phospholipase A2 genes
Molecular
Molecular phylogeny of group-I phospholipase A2 genes. Amino acid dataset with Bayesian posterior probabilities shown along
branches.
followed by recruitment into the venom gland and the
emergence of toxic functions. Also within group-I, a clade
containing neurotoxins from Laticuadata has emerged
from antiplatelet enzymes; the nested position of this
clade indicates that the neurotoxic effect of these enzymes
is derived from more ancestral antiplatelet enzymes. The

origin of group-II toxins that target muscle is also associated with a gene duplication event. Group-II myotoxins
share a unique amino acid substitution at residue 49
(aspartate to lysine) that abolishes enzymatic activity
[13,14]. Thus, Lys49-myotoxins evolved a novel nonhydrolytic mechanism to induce membrane damage [15,16]

Page 5 of 14
(page number not for citation purposes)

http://www.biomedcentral.com/1471-2148/7/2

7
13
78 33
08 81 5
ni5 087 813 8
o
7 56
nd ni5 8
ta do i50 74 62
on n on i508 745
m ta d
a. on an on 08
V. a.m ont and tes5 2
. .m nt
2
V .a
dy 45
o
V a.m mo 087 526 0
V. a.am rus5 0874 453
32
V. b.be rus5 087
24 745
V. b.be rus5 8745 s508
V. .b.be us50 beru 28
V
er erus 745
.b
8
8
V.b erab s50 7453
Vip .beru s508 78149
55
V.b .beru 508
V.b .aspis 60
45
V.a .8717 08781
V.a spis5
8
1
.a
V.a .29613 87815
99
V.a spis50
1
.a
V.a 33464
99
V.a.1 442
153
4
878
V.a.6 spis50
5
143
V.a.a pis50878 ella3161
h
99
.a.as elliiPulc
V ss
5253
4842
DRu
hella
665
.Pulc
63
D.r
5992
99
llatus2
E.oce ns62547939
B.arieta ri37785827
ge
99
5
T.stejne
9
9
ri3778582
T.stejnege
77
squamatus 9
98
P.smucro
s698060
A.HalysPalla
84
7
Pallas2221862
98
A.h.
97
G.halys2460025
T.flavoviridis21698860

94

98

54

61

52

70

78

86

99

54

99
98

99

74

98
89

93

89

74

92

98

90

91

98

98

76

62

98
95

98

64
96

90

96

96

94

96

74

60

94

74

95

88

97

65

98

99

96

98

human
V.a.aspis50874338
V.a.aspis50874398
V.a.aspis50874354
V.a.atra50874366
V.a.zinnikeri331
87134
V.a.aspis508
74396
V.a.aspis
50874342
V.b.beru
s5087432
6
V.a.as
pis508
74344
V.b.be
ru
84
V.a.atra s5087433
508743 0
V.a.a
68
V.a.a spis5087
42
sp
V.a.z is50874 62
348
in
V.a.a nikeri50
58
8742
79
V.a.a tra508
66
74
s
V.b.b pis508 362
V.a erus5 74260
.a
0
V.a tra508 874324
V.a .atra50 74356
56
V.b .zinnik 8743
60
.b
e
V.a erus ri508
V.a .aspis 50874 74320
V.a .asp 508 332
V.a .asp is508 74350
V.a .asp is508 7428
V.a .asp is50 742 8
V. .mo is50 8742 90
V. a.am ntan 8743 92
88
V a.3 mo do
V. .a.ru 3187 dyte ni508
V a.a ffo 13 s50 743
87 84
V. .a.a spis i508 2
43
V. b.be spis 508 742
74
b. ru 50 74 54
be s
ru 50 874 304
s3 87 30
31 43 2
87 10
13
6

4
33
74
08 52
ii5 42 4 0
sin 087 429 585
ur
7 8
ra oi5 08 38 894
8
7
pe uff 5 e
3
Vi .a.r spis stina ni23 654 8584
V a.a lae ho 93 38
V. .pa cma s13 inae
V ma ratu est 80
E. colo pala 744 4476
E. era a508 087 2
Vip .atr pis5 7448 72
V.a.a.as 508 744 8
8
a
5
V
.atr is50 744 4
V.a .asp i508 7444
V.a .ruffo is508 4416
84
V.a .asp s5087 126
V.a .beru 3187 74
V.b erus3 08744 2
5
.b
44
V.b .aspis 0874 0
V.a .aspis5 87443
V.a spis50 74448
08
.a
2
V.a spis5
445
V.a.a pis5087 4402
s
7
V.a.a spis508 438
V.a.a pis50874
s
436
V.a.a
0874
spis5 874464
V.a.a
erus50 4410
V.b.b
is5087
V.a.asp 0874440
pis5
486
V.a.as
s50874 8
modyte
V.a.am odytes5087448
V.a.amm
74432
V.a.aspis508
874424
V.a.aspis50
874490
V.a.ammodytes50
V.a.montandoni50874510
V.a.montandoni50874508
V.a.montandoni50874506

V
Vi .a.
p
z
Vi oxi inn
po nC ik
x h er
V. inC ain i50
h B 8
a
V. .asp ain 291 781
E. a.
is5 B1 45 99
a
C
E.c
E. arin spis 08 294 37
at 33 78 19
arin
E ca
atu .colo rinat us40 187 167
ss
rat us3 88 140
E.p
oc
us 09 92
h
yra
mid B.ar urek 1393 8391 59
ie
i2
V.r umle tans 599 6545 8
.sia
a
2
6
me keyi2 254 661
99
n
Da
5 7
bo sis30 992 945
iar
66
1
V.a
P uss 421 3
99
.zin .field elii64 40
99
i13
nik
45
eri5 451 5
V
087 82
V.a .a.asp
42
.z
is
V.a innike 50874 38
ri3
.z
2
V.a innikeri 31871 32
.zin
508
14
nike
ri50 74246
V.a.a
spis 87424
508
98
8
7
98
Vipo
V.a.1 4228
4083
V.a.m xinChain
99
14
eridio
A
nalis4 291453
Vipox
8425 6
inCha
249
inA16
Vipox
9749
96
40
inAch
88
D.r.russ ain2851544
el
B.schle lii87130860
gelii871
30858
D.r.russe
llii87130
84
854
V.r.siamensi
s31790290
E.macmaho
ni237893
V.ursinii508744
66
V.a.meridionalis50874500
V.a.meridionalis50874502
91
V.a.meridionalis50874496

75

84

82

B.
jar
a
Pir rac
a us
B. toxin su5
Pir
A.
II 18
P.
A. pisc ajai1 I178 903
mu
cro pis ivo 69 65 98
s civ ru
7 5
P. quam oru s26 491 40
ele
s3 39 9
a
g
T.f T.fla ans tus5 003 60
1 9
lav vo
8
ov virid 457 749 5
B.j B.ins iridis is22 888 0
B.J arara ularis 1579 295 9
9
c
a
9
98
B.J rarac ussu 2006 265
ara
9
2
u
rac ssu3 5140 137
99
u
7
3
A.H ssu93 9282 77
3
aly
2
T.s
s2 785 2
te
T.s jnege 8948 29
99
tejn
ri37
59
A.p egeri3 78586 0
is
7
7
D.A civoru 78586
cutu s30
1
03
s1
S.c.t D.acutu 81587894
s
erge
7
minu 902653
C.rho
26
s459
d
3
C.rho ostoma6 4756
07
dosto
ma60 3843
99
C.rho
738
do
C.rhod stoma607 41
99
ostom
38
a60738 39
T.stejne
37
geri3
98
98
C.v.virid 7785865
is29692
356
C.v.virid
is29692
99
352
C.v.viridis
99
29692354
C.atrox172
99
24437
99
C.v.viridis29692
350
98
C.v.viridis28893824
71
V.a.montandoni28893826
99
C.v.viridis28893822
99
S.c.tergeminus45934758
100
C.scutulatusscutulatus451316
98
C.durissus62686
B.pictus9652397
50426
B.erythromelas864 948
nsis38146
73
G.shedaoe
59
eri377858
T.stejneg
us430833
4
T.gramine
97
4427
ineus16 834
T.gram
30
98 98
ineus4
T.gram s1769398
8
9
avensi s263545
isokin
98
mineu 30145
Ovoph
T.gra
s382 0135
eensi
23
T.born niceus38 0139
98
3
T.pu
s382 85863
u
nice
77
T.pu egeri3 29502
tejn
in1 7120
T.s
dox 8
6
Cau rus331
085
.be
5
713
V.b
llii8 90928 3
5
sse
0
.r.ru nsis3 lii644 81
D
me usse 451 0
ia
D.r ldi13 9994
V.r.s
3
1
ie
P.f kii91 7817 3
ls
08 819 7
iko
ri5
V.n nike i5087 7818 9
.zin niker i508 7816 7
9
V.a in iker 08
.z n
81 9
i5
V.a .zin iker 087 815 2
V.a .zinn eri5 5087 994 95
ik
9
a
V. .zinn spis 911 781 118
9
8
ii
.a
a
V. V.a olsk ri50 187 817 5
e i33 87 31
nik ik
V. zinn iker ri50 408
n e .1
a.
V. a.zin nik V.a
V. a.zin
V.

99

98

97
T.puniceus38230131
90
T.puniceus38230133
98
95
T.stejnegeri37785857
829
T.stejnegeri37785
91
85833
T.stejnegeri377 275
644
T.gramineus1
1
71 98
ri3778583
92
T.stejnege
8891
ns8457
69
P.elega
893
s84578
P.elegan uamatus83
99
35
rosq
P.smuc toma60738
77 76
os
55
2229
C.rhod
viridis
BPI
74 99
T.flavo
35
2244
98
ox17 cinct
ti
C.atr
rixla
57
98
601
ntort
A.co tortrix4 G K P I
on
A
18
A.C
325 0
i174 252
geli i1743 56
51
1
n
chle
B.s odma 17433 600
II
8
22
C.g
xin
II31 887
oto
My otoxin 4088 2260
My .atrox r649 017
B spe 673 60
B.a jeni7 655 3
8
97
oo
17 71 5
B.m jTXII II11 6832 8
M xin 73 411 9
9
oto I1
1
My toxin u281 730 54
o
6
1
s
My cus sis7 433 328 2
ara loen I17 368 591 1
in
jar
B. ipau x II17 083 505 57
ato
ied Pir oxin i1 26 31
at iraja ssu 43
uw
ne
Pir .P acu I17
B.
B ar
xin
jar to
B. B.

T.borneensis38230143
D.acutus17224439
D.acutus2760481
C.rhodostoma60
73833
B.jararacussu2
8194389
99
MyotoxinI12
9400
70
T.flavov
54
iridis282
T.flavovir
68779
idi
98 81
P.mucro s28268777
squam
98 96
atus15
D.acu
420985
tus902
65327
S.m.s
S.c.te treckeri382
rg
30
98
C.v.v eminus38 121
2301
iridis
98 97
C.go
27
dma 333373
39
ni38
B.sc
2
C.d hlegelii 30123
98 98
uri
38
S.c.t ssus62 230125
erge
693
C.d
min
u
99
Agk rissus6 us382
A.H istroto 2697 30129
99
A.H alysP xin12
99
9
a
a
T.je lysP llas4 437
P.m rdon allas5 3894
94
821 03
T.b ucro ii209
8
T.p orne squa 77211 35
en
T.s unic
sis matu
V.a tejne eus3 3823 s763
82
01
62
V. .12 geri3 30
22
4
77 137 7
V a.2 948
85
V. .a.a 4233 1
86
9
V. a.am mm 4
V. a.am mo odyt
V. a.r m dy es5
V. a.amuffo ody tes2 087
i5
2
a.
m mo 08 tes5 311 4542
on
0
d 7
2
ta yte 453 874 2
nd
s 6
55
on 508
6
i50
74
56
87
0
81
39

BMC Evolutionary Biology 2007, 7:2

Figure 4 phylogeny of group-II phospholipase A2 genes
Molecular
Molecular phylogeny of group-II phospholipase A2 genes. Amino acid dataset with Bayesian posterior probabilities shown along
branches

after duplication of an ancestral Asp49-PLA2 that was not
myotoxic.
I used maximum likelihood models of coding-sequence
evolution [17,18] to test the hypothesis that functional
diversification of snake venom PLA2 genes is driven by
positive Darwinian selection. This method determines the
strength and direction of selection by estimating the non-

synonymous-to-synonymous substitution rate (dN/dS =
Ï), with Ï = 1, <1, and >1 indicating neutral evolution,
purifying selection and directional selection, respectively.
The branch-specific one-ratio model is the simplest, estimating the same Ï for all branches in the phylogeny. The
estimate of Ï for group-I genes under this model, 1.28, is
an average over all codons and lineages, highlighting the
dominant role of positive selection on elapid venom

Page 6 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

phospholipases. The estimate of Ï for group-II genes
under the one-ratio model, 0.686, indicates that group-II
genes are generally under purifying selection, however,
this estimate is higher than reported from most genes.

diversification of vipers and elapids and their venoms. It
also suggest lineages which can be targeted for ancestral
sequence reconstructions for characterization of ancestral
toxin functions to compare extant functions to.

The one-ratio model can only detect adaptive evolution
when the majority of amino acids and lineages under
study have been under positive selection (such as in
group-I genes). If adaptive evolution is primarily episodic,
then short episodes of positive selection, which are followed by long periods of purifying selection, will not be
detected. To test for episodes of positive selection in
group-I and group-II gene lineages, I used a free-ratios
model that estimates separate dN/dS ratios for all lineages
in the tree. These models fit the data significantly better
than either the one-ratio model or a constrained one-ratio
model with Ï forced to be 1 (group-I genes) or a free-ratio
model with lineages previously identified with Ï >1 constrained to be 1 (group-II genes), indicating that episodes
of directional selection are common in snake venom PLA2
evolution with nearly 32% and 21% of group-I and -II
gene lineages, respectively, having been under directional
selection (Figs. 1 and 2). Moreover, there are several
branches with extremely high Ï values, including two
group-I and three group-II branches with Ï >3, one groupI branch with Ï >5 and one group-I branch with Ï = 9.06
(Figs. 1 and 2).

The importance of gene duplication to the evolution of
species-specific traits is relatively unknown, but duplications resulting in species-specific adaptations have been
demonstrated for some genes [20,21]. The unexpectedly
high group-I ÏPS may be the result of enzyme adaptation
to new prey preference after speciation. Indeed, the three
semi-aquatic kraits (Laticaudata sp.) prey primarily on
moray and conger eels and assorted fishes [22,23] while
Australian copperheads (Austrelaps) prey on frogs and lizards [24]. In the Elapinae group, the king cobra (Ophiophagus hannah) and kraits (Bungarus sp.) feed almost
exclusively on snakes and other reptiles [25], while the
true cobras (Naja sp.) and the Eastern brown snake (Pseudonaja textilis) feed on small mammals, amphibians and
birds [25]. This pattern suggest a scenario where dietary
shifts after speciation runs the PLA2 gene repertoire
through a "selective sieve"; those genes which are no
longer effective in subduing new prey species are lost,
while genes that are still effective adapt to the new prey
type and subsequently diversify.

Ohno's model [19] of post-duplication divergence predicts an increase in the nonsynonymous substitution rate
following duplication as positive Darwinian selection
drives the fixation of mutations that confer new or modified functions on gene duplicates. To test for accelerated
evolution after duplication I used smaller datasets for
which speciation and duplication events could be unambiguously assigned to each branch and a two-ratios model
that estimated different Ï parameters for post-duplication
(PD) and post-speciation (PS) branches. Surprisingly, in
group-I genes PD and PS branches have nearly identical Ï
values (ÏPD = 1.12, ÏPS = 1.22), indicating that positive
selection is associated with both gene duplication and
speciation. In contrast to group-I genes, group-II gene PD
branches evolve much faster than PS branches (ÏPD = 1.4,
ÏPS = 0.63), consistent with the classical model of neofunctionalization.
Here, neofunctionalization is defined as the emergence of
a new toxic effect from an ancestral enzyme that did not
posses that effect as its main toxin function (for example,
neurotoxic Laticuadata genes and Lys49-myotoxins discussed above). Strikingly, positive selection occurred in
the stem-lineage of 67% (4/6) of group-I functional
groups and 88% (7/8) of group-II functional groups (Figs.
1 and 2) indicating that positive selection played a pervasive role in the origin of novel toxin functions during the

A limitation of the lineage-specific models of protein evolution utilized above is that they can only detect directional selection when the average Ï over all amino acids
in the protein is >1. Thus, lineage-specific models have
limited ability to detect short episodes of directional selection that affect only a few amino acids or amino acids
under recurrent diversifying selection. Site-specific models [26] account for rate variation among sites and are
powerful tools for detecting diversifying selection. I used
three pairs of site-specific models to test for recurrent,
diversifying, selection: M0 (one ratio) and M3 (Discrete),
M1 (Neutral) and M2 (Selection), and M7 (Beta) and M8
(Beta & Ï). Parameter estimates under models M2, M3
and M8, which allow for sites with Ï >1, identified that up
to 65% of sites in group-I genes and 27% of sites in groupII genes are under positive selection (Tables 1 and 2). This
is strong evidence that diversification of snake venom
PLA2 genes is driven by recurrent positive selection and
suggest that venomous snakes are caught in a co-evolutionary arms race with prey as prey evolve resistance to the
current venom arsenal and snakes evolve ever more toxic
venoms.
The three dimensional structure of PLA2 enzymes are
extremely conserved, obscuring the mechanisms that produce such a wide spectrum of pharmacological effects. To
investigate how functional diversity is generated in PLA2
enzymes, I mapped sites that were identified as being
under diversifying selection on to the crystal structure of

Page 7 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

Table 1: Maximum Likelihood Parameter Estimates for Group-I PLA2 Genes.

á

Ï0

Parameters

Sig.

-9102.48
-9106.69
-5153.65
-5153.55
-8980.48

1.28
1
1.16

= Ï0
Ï0 constrained to 1
= Ï0
ÏPD = 1.22, ÏPS = 1.12
see Figure 1

P < 0.01

-8909.37

0.852

M2: selection...

-8600.95

2.11

M3: discrete.....

-8540.48

1.69

M7: beta...........
M8: beta&Ï......

-8725.96
-8544.24

0.594
1.4

Model
Lineage-specific
M0: one ratio...
M0: one ratio-C
M0: one ratio-2
PD-PS.............
Free ratio.........
Site-specific
M1: neutral.......

p0 = 0.148, Ï0 = 0
p1 = 0.582, Ï2 = 1
p0 = 0.145, Ï0 = 0
p1 = 0.5, Ï2 = 1
p2 = 0.355, Ï2 = 4.53
p0 = 0.343, Ï0 = 0.115
p1 = 0.435, Ï2 = 1.43
p2 = 0.222, Ï2 = 4.63
p = 0.266, q= 0.182
p0 = 0.70, p = 0.276, q = 0.228
p1 = 0.297, Ï = 3.41

Positive Sites

n.s.
P << 0.001

36 (PP â¥ 0.99)
4 (0.95 â¤ PP < 0.99)
10 (PP < 0.95)
74 (PP â¥ 0.99)
7 (0.95 â¤ PP < 0.99)
4 (PP < 0.95)

P << 0.001

P << 0.001

28 (PP â¥ 0.99)
2 (0.95 â¤ PP < 0.99)
9 (PP < 0.95)

P << 0.001

L is the log likelihood of the model; Ï0 is the estimate of the dN/dS ratio under the model (given as a weighted average for the site-specific models);
Sig. is the significance of the model when compared to it's neutral partner under the Ï2-distribution; Positive sites gives the number of sites that fall
within a particular Baysean posterior probability value (PP) of being in the site class Ï >1. n.s., not significant.

group-I and -II phospholipases (Fig. 5). The vast majority
of amino acids under diversifying selection occur outside
of the Î±-helicical central scaffold and in regions of the
protein that form connecting loops, however, the scaffold
of group-II proteins is more conserved than group-I proteins. Functionally important residues, including cysteins
that participate in disulfide bonds, the catalytic triad, the

calcium-binding site and the hydrophobic channel have
dN/dS ratios near zero indicating these regions are under
strong structural and functional constraint. In contrast,
there are several clusters of amino acids on the molecular
surface under intense diversifying selection in both groupI and -II proteins (Fig. 5). These rapidly evolving regions
are similar to sites known to produce toxic effects in PLA2

Table 2: Maximum Likelihood Parameter Estimates for Group-II PLA2 Genes.

á

Ï0

Parameters

Sig

-11770.60
-4303.29
-4300.30
-11580.19
-11591.23

0.686
0.694

1

= Ï0
= Ï0
ÏPD = 1.41, ÏPS = 0.63
see Figure 1
Ï0 constrained to 1

P = 0.014
P << 0.001
P << 0.01

-11547.79

0.876

M2: selection...

-11266.10

1.64

M3: discrete.....

-11096.30

0.971

M7: beta...........
M8: beta&Ï......

-11179.33
-11073.18

0.532
0.899

Model
Lineage-specific
M0: one ratio...
M0: one ratio-2
PD-PS..............
Free ratios.......
Free ratios-2....
Site-specific
M1: neutral.......

p0 = 0.124, Ï0 = 0
p1 = 0.876, Ï2 = 1
p0 = 0.124, Ï0 = 0
p1 = 0.605, Ï2 = 1
p2 = 0.271, Ï2 = 3.81
p0 = 0.346, Ï0 = 0.078
p1 = 0.42, Ï2 = 0.83
p2 = 0.234, Ï2 = 2.55
p = 0.332, q = 0.293
p0 = 0.81, p = 0.352, q = 0.348
p1 = 0.19, Ï = 2.58

Positive Sites

P << 0.001

P << 0.001

P << 0.001

30 (PP â¥ 0.99)
2 (0.95 â¤ PP < 0.99)
9 (PP < 0.95)
21 (PP â¥ 0.99)
5 (0.95 â¤ PP < 0.99)
8 (PP < 0.95)
15 (PP â¥ 0.99)
7 (0.95 â¤ PP < 0.99)
6 (PP < 0.95)

L is the log likelihood of the model; Ï0 is the estimate of the dN/dS ratio under the model (given as a weighted average for the site-specific models);
Sig. is the significance of the model when compared to it's neutral partner under the Ï2-distribution; Positive sites gives the number of sites

Page 8 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

A

B

0

D

C

1.0

>3

F

E

Figure 5
The structure of group-I (A-C) and group-II (D-F) phospholipase A2 proteins
The structure of group-I (A-C) and group-II (D-F) phospholipase A2 proteins. The structures are represented by ribbons in A
and D with disulfide bonds and catalytic residues shown as sticks and as molecular surfaces rendered in 3D in B, C, E and F.
Residues are colored coded according to their approximate posterior mean Ï (scale shown between rows) calculated under
model M3 (discrete). B and E are in the same orientation as A and D, respectively, while C and F are rotated 180Â° about a horizontal axis through the molecule.
enzymes [27-29], highly suggesting that regions under
positive selection on the proteins surface are responsible
for generating toxic functions.
Although positive selection is often associated with the
origin of novel toxin functions (such as antiplatelet, neurotoxic and procoagulent toxins), there are several lineages in which new functions emerge without a significant
increase in the nonsynonymous substitution rate (other
neurotoxins and cardiotoxins). This is not unexpected
since it has long been known that relatively few amino
acid changes can have drastic effects on protein functions
[ref], suggesting some lineages may have substitutions
that contribute to the origins of novel functions but that
might have been missed in the lineage and site-specific
analyses above. To further clarify the pattern of amino
acid replacement that promotes functional changes, I
mapped amino acid changes inferred from ancestral
sequence reconstructions for select group-I (Figs. 6 and 7)
and group-II genes (Fig. 8) onto the crystal structure of
these proteins. Clearly, replacements are nearly evenly distributed on protein surface in both group-I and -II genes,

but there are several regions that are devoid of amino
acids changes including residues in and around the active
site and patches of conserved residues on the "back" of the
proteins. These regions also contain residues in the slowest evolving site-class from the site-specific analysis. Taken
together, these patterns suggest that while only a few
changes on the surface are needed to evolve a new function, there are regions under strong structural/functional
constraints that limit divergence such as the hydrophobic
core and patches of conservation on the surface. Given
this, it is interesting to note that several basal clades in the
group-II genes with uncharacterized pharmacological
effects have strong evidence of selection and many amino
acid replacements that map to the surface (Figs. 2 and 8)
suggesting that they may have evolved novel, if as of yet
unidentified, functions.

Conclusion
The molecular evolution of group-I and group-II PLA2
genes, such as the birth and death like and "selective
sieve" processes of gene duplication, divergence and loss
are similar to evolution of other snake venom proteins,

Page 9 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

Figure 6
Ancestral sequence mapping for hydrophiinae group genes
Ancestral sequence mapping for hydrophiinae group genes. The upper left panel shows the generalized phylogeny while each
additional panel shows the cumulative amino acid changes that occurred for that lineage. Amino acids in panels A-E are colored
by the lineage they changed in. For example, amino acid changes that occurred in the stem-lineage of neurotoxic genes (lineage
C, panel C) are colored X; amino acid changes that occurred in ancestral lineages of neutrotoxins are colored Y and Z. In each
panel the top two structures are shown with the molecular surface and the bottom structures are ribbons. Structures on left
and right are rotated about a central axis 180Â°. Cystienes are shown in yellow

Page 10 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

Figure 7
Ancestral sequence mapping for elapinae group genes
Ancestral sequence mapping for elapinae group genes. Organization follows Figure 6.

Page 11 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

Figure 8
Ancestral sequence mapping for group-II genes
Ancestral sequence mapping for group-II genes. Organization follows Figure 6. Antipla., antiplatelet. Chp., chaperone. UnChar.,
genes with uncharacterized pharmacological effects.

Page 12 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

particularly the elapid three-finger toxins [30]. Indeed,
there is even evidence for species-specific toxin adaptation
to prey type within the three-finger toxins and maintenance of a well-ordered tertiary structure [30] similar to
that seen in PLA2 genes, suggesting that this mode of
molecular evolution may be common in venom genes.
Kini and Evans [5] have proposed that 'target sites' on the
surface of prey cells are recognized by 'pharmacological
sites' on PLA2 enzymes. These protein-protein interactions
determine PLA2 specificity by having complementary
charges, hydrophobicities, and Van der Waals contact surfaces. This model, combined with the analyses above, suggest that entirely new functions originate after duplication
through substitutions in pharmacological sites that alter
binding specificities. Although most substitutions will
likely disrupt binding specificity for the current target site,
a few may create new interaction sites leading to the emergence of novel functions.
The extraordinary level of positive selection acting on
snake venom phospholipase A2 genes indicates that adaptive molecular evolution plays an important role in the
emergence of these novel functions, continues as functions are diversified and refined, and may contribute to
niche differentiation after speciation. Interestingly, mapping sites under positive selection onto the structure of
PLA2 enzymes has identified regions that are attractive
candidates for structure-based drug design. These data
also demonstrate that increases in genomic complexity
gained through gene duplications has lead to an increase
in phenotypic complexity (venom composition) and
likely the ability of venomous snakes to adapt to new prey
types.

Methods
Sequence alignment and phylogenetic reconstruction
PLA2 genes were obtained from public database (GenBank
GI's for each gene are shown in Figs. 1 and 2 for nucleotide data and in Figs. 3 and 4 for amino acid data). Partial
sequences, sequences with insertions-deletions that
caused reading frame shifts and sequences with premature
stop codons were excluded from analysis as likely pseudogenes in the nucleotide analysis. Group-I and -II protein
sequences were aligned in Clustal W [31] and adjusted by
eye using Se-Al. Bayesian phylogenetic analyses were performed using MrBayes v3.0 [10]. Tree searches were run
using four Markov chains for 3,000,000 generations saving every 100th tree and a codon-based GTR+Î+I model of
sequence evolution or a JTT+Î+I model for amino acid
data. Models are nucleotide and amino acid data were
selected using ModelGenerator. After stationarity, the
final 15000 trees were used to build a consensus tree. Each
analysis was performed three times to ensure convergence
of tree topologies.

http://www.biomedcentral.com/1471-2148/7/2

Tests for selection and ancestral sequence reconstructions
I used codon-based maximum likelihood models implemented in CODEML in the PAML package of programs
(version 3.14) [32] to test for lineages under positive
selection using the one-ratio and free-ratios models; this
package of programs was also used for ancestral sequence
reconstructions. To test for differences in post-duplication
(PD) and post-speciation (PS) branches I used a smaller
dataset of group-I and -II genes that included at least five
representatives of each species/pharmacological group
and for which gene duplication and speciation events
could accurately be assigned for each branch. Twice the
log likelihood difference between models, 2Îá = 2(á1-á0),
is compared to a Ï2-distribution with the degrees of freedom equal to the number of parameter differences
between the models to test whether the alternative model
(free-ratio or PD-PS) fits the data significantly better than
the null model (one-ratio). If a lineage has a dN/dS > 1 and
the likelihood ratio test is significant, than the neutral
model of evolution is violated and positive selection is
suggested. To explicitly test for positive selection I used
constrained models that fixed Ï at 1.

I used three pairs of site-specific models [33] to identify
specific amino acids under diversifying selection: M0 and
M3 (discrete), M1 (neutral) and M2 (selection), and M7
(beta) and M8 (beta & Ï). Model M0 estimates a single Ï
parameter for all sites and branches, while model M3 (discrete) estimates three independent Ï parameters and the
proportion of sites belonging to each Ï-class directly from
the data. Model M1 (neutral) assumes two classes of sites
in the protein with the proportion of conserved sites (Ï =
0) and neutral sites (Ï = 1) estimated from the data, while
model M2 (selection) adds a third site class with an additional Ï estimated as a free parameter allowing for sites
with Ï > 1. Model M7 (beta) uses a beta distribution B(p,
q) with Ï restricted to the interval (0,1) while Model M8
(beta & Ï) adds a site class with the Ï and the proportion
of sites with that Ï estimated from the data, allowing for
sites with Ï > 1. Twice the log likelihood difference
between the models is compared to the Ï2 distribution
and tests for variation in Ï among sites. After maximum
likelihood parameter estimates are calculated, the Bayes
theorem is used to calculate the posterior probability of
belonging to a site class, when a site is identified with Ï >
1 than positive selection is indicated. Sites with posterior
probabilities of > 0.5 are reported here. The approximate
posterior mean Ï for each site from model M3 with two
site classes were mapped onto the crystal structures of
group-I (PDB ID: 1A3D) and -II (PDB ID: 1OZ6) PLA2
proteins using ICM-Browser (available from http://
www.molsoft.com) or Chimera. The three-dimensonal
space filling structures were generated with Deep View â
spdbv v3.7 [34].

Page 13 of 14
(page number not for citation purposes)

BMC Evolutionary Biology 2007, 7:2

http://www.biomedcentral.com/1471-2148/7/2

Authors' contributions

16.

VJL designed the study, carried out the statistical analyses
and drafted the manuscript. All authors have read and
approved the final manuscript.

17.

Acknowledgements

18.

I thank G. P. Wagner for helpful comments and discussion of the manuscript and Z. Yang for answering questions regarding the use of PAML. I also
thank M. J. McCarron for careful reading of the manuscript and the anonymous reviewers for their comments. Support for this research was provided by departmental graduate student research funds provided to VJL.

19.
20.

References

22.

1.
2.
3.

4.

5.
6.

7.

8.

9.
10.
11.

12.

13.

14.

15.

Dennis EA: Phospholipases. In The Enzymes Volume 16. 3rd edition.
Edited by: Boyer PD. New York, Academic Press; 1983.
Kini RM: Venom Phospholipase A2 enzymes: Structure, Function and Mechanism. Chichester, Wiley; 1997:511.
Kini RM, Evans HJ: The role of enzymatic activity in inhibition
of the extrinsic tenase complex by phospholipase A2 isoenzymes from Naja nigricollis venom.
Toxicon 1995,
33:1585-1590.
Rufini S Cesaroni, M.P., Balestro, N., Luly, P.: The proliferative
effects of ammodytin L from the venom of Vipera ammodytes on 208F rat fibroblasts in culture. Biochemical Journal
1996, 320:318-326.
Kini RM, Evans HJ: A model to explain the pharmacological
effects of snake venom phospholipases A2. Toxicon 1989,
27:613-635.
Chuman Y, Nobuhisa I, Ogawa T, Deshimaru M, Chijiwa T, Tan NH,
Fukumaki Y, Shimohigashi Y, Ducancel F, Boulain JC: Regional and
accelerated molecular evolution in group I snake venom
gland phospholipase A2 isozymes. Toxicon 2000, 38:449-462.
Nakashima K, Nobuhisa I, Deshimaru M, Nakai M, Ogawa T, Shimohigashi Y, Fukumaki Y, Hattori M, Sakaki Y, Hattori S, Ohno M: Accelerated Evolution in the Protein-Coding Regions is Universal
in Crotalinae Snake Venom Gland Phospholipase A2 Isozyme Genes. PNAS 1995, 92:5605-5609.
Kordis D, Bdolah A, Gubensek F: Positive Darwinian Selection
inVipera palaestinaePhospholipase A2Genes Is Unexpectedly Limited to the Third Exon. Biochemical and Biophysical
Research Communications 1998, 251:613-619.
Kini RM Chan, Y.M.: Accelerated evolution and molecular surface of venom phospholipase A2 enzymes. Journal of Molecular
Evolution 1999, 48:125-132.
Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic
inference under mixed models.
Bioinformatics 2003,
19:1572-1574.
Slowinski JB, Knight A, Rooney AP: Inferring Species Trees from
Gene Trees: A Phylogenetic Analysis of the Elapidae (Serpentes) Based on the Amino Acid Sequences of Venom Proteins. Molecular Phylogenetics and Evolution 1997, 8:349-362.
Fujimi TJ, Kariya Y, Tsuchiya T, Tamiya T: Nucleotide sequence of
phospholipase A2 gene expressed in snake pancreas reveals
the molecular evolution of toxic phospholipase A2 genes.
Gene 2002, 292:225-231.
Maraganore JM, Heinrikson RL: The lysine-49 phospholipase A2
from the venom of Agkistrodon piscivorus piscivorus. Relation of structure and function to other phospholipases A2
[published erratum appears in J Biol Chem 1993 Mar
15;268(8):6064]. J Biol Chem 1986, 261:4797-4804.
van den Bergh CJ Slotboom, A.J., Verheij, H.M., de Haas, G.H.,: The
role of aspartic acid-49 in the active site of phospholipase A2.
A site-specific mutagenesis study of porcine pancreatic phospholipase A2 and the rationale of the enzymatic activity of
[lysine49]phospholipase A2 from Agkistrodon piscivorus piscivorus' venom.
European Journal of Biochemistry 1998,
176:353-357.
Diaz C Gutierez, J.M., Lomonte, B., Gene, J.A.: The effect of myotoxins isolated from Bothrops snake venoms on multilamellar liposomes: relationship to phospholipase A2,
anticoagulant and myotoxic activities. Biochim Biophys Acta
1991, 1070:455-460.

21.

23.
24.
25.
26.
27.
28.

29.
30.

31.

32.
33.
34.

Rufini S Cesaroni, P., Desideri, A., Farias, R., Gubensek, F., Gutierrez,
J.M., Luly, P., Massoud, R., Morero, R., Pedersen, J.Z.: Calcium ion
independent membrane leakage induced by phospholipaselike myotoxins. Biochemistry 1992, 31:12424-12430.
Goldman N, Yang Z: A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol Biol Evol
1994, 11:725-736.
Yang Z: Likelihood ratio tests for detecting positive selection
and application to primate lysozyme evolution. Mol Biol Evol
1998, 15:568-573.
Ohno S: Evolution by Gene Duplication. Berlin, Springer; 1970.
Zhang J , Zhang, Y., Rosenberg, H.F: Adaptive evolution of a duplicated pancreatic ribonuclease gene in a leaf-eating monkey.
Nature Genetics 2002, 30:411-415.
Riehle MM, Bennett AF, Long AD: Genetic architecture of thermal adaptation in Escherichia coli. PNAS 2001, 98:525-530.
Shine R Reed, R. N., Shelty, S., Cogger, H. G.: Relationships
between sexual dimophism and niche partitioning within a
clade of sea snakes (Laticaudinae). Oecologia 2002, 133:45-53.
Su Y Fong, S.-C., Tu, M.-C.: Food Habits of the Sea Snake, Laticauda semifasciata. Zoological Studies 2005, 44:403-408.
Shine R: Habitats, diets, and sympatry in snakes: a study from
Australia. Canadian Journal of Zoology 1977, 55:1118-1128.
Oriov N Ananjeva, N., Ryabov, S., Rao, D.-Q.: Venomous snakes
of southern China. Reptilia 1992, 31:22-29.
Yang Z Bielawski, J. P.: Statistical Methods for detecting molecular adaptation.
Trends in Ecology and Evoltuion 2000,
15:1994-1997.
Kini RM: Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. Toxicon
2003, 42:827-840.
Chioato L, Ward RJ: Mapping structural determinants of biological activities in snake venom phospholipases A2 by
sequence analysis and site directed mutagenesis. Toxicon
2003, 42:869-883.
Soares AM, Giglio JR: Chemical modifications of phospholipases A2 from snake venoms: effects on catalytic and pharmacological properties. Toxicon 2003, 42:855-868.
Fry BG WW Kini RM, Brusic V, Khan A, Venkataraman D, Rooney
AP.: Molecular evolution and phylogeny of elapid snake
venom three-finger toxins. Journal of Molecular Evolution 2003,
57:110-129.
Higgins D Thompson, J., Gibson, T., Thompson, J.D., Higgins, D.G.,
Gibson, T.J.: CLUSTAL W: improving the sensitivity of progressivemultiple sequence alignment through sequence
weighting,position-specific gap penalties and weight matrix
choice. Nucleic Acids Research 1994, 22:4673-4680.
Yang Z: PAML. a program package for phylogenetic analysis
by maximum likelihood. CABIOS 1997, 13:555-556.
Yang Z, Nielsen R, Goldman N, Pedersen AMK: Codon-Substitution Models for Heterogeneous Selection Pressure at Amino
Acid Sites. Genetics 2000, 155:431-449.
Guex N Peitsch, M.C.: SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling.
Electrophoresis 1997, 18:2714-2723.

Publish with Bio Med Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical researc h in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours â you keep the copyright

BioMedcentral

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Page 14 of 14
(page number not for citation purposes)

</pre>
</body>
</html>
